SMi presents the 13th annual industry leading conference: Cold Chain Distribution

SMi Group10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

The two-day event will also look at various developments within the industry, guiding companies on how best to ensure costs are kept low, and quality remains high, whilst simultaneously staying compliant to global regulations.

This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution.

Chairs for 2018

  • Bob Hayes, Director, SeerPharma (UK)
  • Tony Wright, CEO, Exelsius

Featured Speakers

  • Bob Hayes, Director, SeerPharma (UK)
  • Stephen Mitchell, Quality Lead Logistics Partnerships, GSK
  • GianneOlaes-Dénis, Supply Chain Quality Manager, SanofiGenzymeEurope
  • Stefan Braun, Managing Director, SmartCAE
  • GianpieroLorusso, Director, Supply Operations and GS, Merck
  • Francicso Rizzuto, Cargo Specialist, Manager for Europe, IATA
  • Marco Gaudesi, Pharmacist - GDP and Cold Chain Referent, MSF
  • Henk Mulder, Head, Digital Cargo, IATA

Key Highlights

  • Evaluate the current GDP guidelines, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice
  • Explore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved
  • Discover the temperature-controlled logistic solutions to best optimize your supply chain
  • Discuss the technical agreements within the supply chain and find out what questions you should be asking
  • Identify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process

View the full agenda online: www.coldchain-distribution.com

  • Register by 29th June and save £400
  • Register by 28th September and save £300
  • Register by 31st October and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...